ANDA 79022, held by Teva Pharms USA. Atomoxetine Hydrochloride.
As of Nov 16, 2026, ANDA 79022 (Atomoxetine Hydrochloride), held by Teva Pharms USA, was first approved by FDA on May 30, 2017, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 30, 2017 | Original application | Approved |
| Atomoxetine HydrochlorideEQ 10MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Atomoxetine HydrochlorideEQ 18MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Atomoxetine HydrochlorideEQ 25MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Atomoxetine HydrochlorideEQ 40MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Atomoxetine HydrochlorideEQ 60MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Atomoxetine HydrochlorideEQ 80MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Atomoxetine HydrochlorideEQ 100MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Apr 7, 2023 | Supplement 7Labeling · Standard review | Approved | None posted |
| Apr 7, 2023 | Supplement 11Labeling · Standard review | Approved | None posted |
| Apr 7, 2023 | Supplement 12Labeling · Standard review | Approved | None posted |
| May 30, 2017 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters